Dave Lennon

Chief Executive Officer • Satellite Bio

Dave Lennon was appointed Chief Executive Officer of Satellite Bio in July 2021. Dave is a 20-year industry veteran driven by the purpose to bring together diverse teams to address the most pressing challenges in medicine to achieve amazing impact for patients and their families.

Prior to Satellite Bio, Dave spent more than 15 years with Novartis working across multiple therapeutics and geographies. He was most recently President, Novartis Gene Therapies, where he led the approval and launch of Zolgensma, the first systemic gene therapy for spinal muscular atrophy that was approved in more than 40 countries. He also led the expansion of Novartis’s gene therapy research and manufacturing footprint to oversee 5 different sites and more than 2,000 associates. By the time of his departure, Novartis’s gene therapy pipeline had expanded to include 15+ new gene therapy programs, and Zolgensma had achieved blockbuster sales.

Prior to Novartis Gene Therapies, Dave served in positions of increasing responsibility across Oncology, Neuroscience, Transplant and Rare Disease therapeutic areas in the U.S., Europe, Japan and China. Key positions included General Manager Oncology Japan, Solid Tumor Franchise Head USA and Chief Marketing Officer China. He started his career at Novartis as Global Head, New Products and Portfolio Strategy.

Prior to Novartis, Dave was an Associate Principal with the New York office of McKinsey & Company, delivering client projects in R&D productivity and consulting in BD&L and M&A transactions.

Dave earned a PhD in Molecular Medicine from Weill Cornell Medical College of Cornell University and BA in Biophysics from Columbia College of Columbia University.

Also Speaking

Michael Lawlor

Professor • Medical College of Wisconsin

Lung-I Cheng

Vice President, Cell and Gene Therapy • AmerisourceBergen

Andrew Olaye

Executive Director, Market Access & Partnerships EMEA • Orchard Therapeutics

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2024.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.